Market Research Report
Physician Views: Let the games begin - Remicade biosimilar free to debut in EU5 markets
|Published by||FirstWord||Product code||326356|
Delivery time: 1-2 business days
|Physician Views: Let the games begin - Remicade biosimilar free to debut in EU5 markets|
|Published: January 30, 2015||Content info:||
The intellectual property barrier that has so far prevented biosimilar Remicade from being launched in Europe's five largest markets (France, Germany, Italy, Spain and the UK) will be lowered next month when Remicade's paediatric extension - awarded in April 2013 - expires.
This is expected - at some point during H1 2015 - to trigger the launch of Celltrion and Hospira's biosimilar infliximab product, which gained EU approval in September 2013 (as the region's first biosimilar monoclonal antibody) and which is sold in various other European markets under a handful of brand names (Remsima, Inflectra, Flammegis).
The performance of Celltrion and Hospira's biosimilar in other markets has been somewhat mixed, although enthusiasm for the product in some countries - such as Norway - has been highly encouraging for the biosimilar community.
In terms of establishing any kind of commercial benchmark for biosimilar antibodies, however, a key test was always going to be measured by uptake of biosimilar infliximab in the region's largest markets.
Quite how this will pan out over the next few years remains unclear; branded manufacturers appear to have become increasingly comfortable with referencing the pending advent of biosimilar competition to key antibody products, but also remain very guarded on both potential revenue impact and the competitive strategies they will use in response.
Furthermore, biosimilar versions of more complex pharmaceuticals - such as infliximab - raise key questions of physician sentiment, which will play a key role in shaping adoption and commercial success.
Thus, with the European biosimilar market on the cusp of significant evolution, FirstWord is this week polling rheumatologists and gastroenterologists based in the EU5 markets to ascertain their opinion towards future biosimilar infliximab usage.
Specifically we are asking them...
Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialities and over 100 markets.